Insights on increasing the translational value of your preclinical development program.
Jun 23, 2026by MD Biosciences
GLP-1 receptor agonists have substantially reshaped the therapeutic landscape for type 2 diabetes and obesity, and the...
Jun 16, 2026by MD Biosciences
Drug development for chronic kidney disease has entered a more ambitious phase. SGLT2 inhibitors, non steroidal...
Jun 9, 2026by MD Biosciences
Chemotherapy induced peripheral neuropathy remains one of the most underserved symptoms in oncology supportive care....
Jun 2, 2026by MD Biosciences
Chronic wounds in diabetic patients are one of the costliest quietly growing burdens in medicine. Roughly 15 to 25...
May 26, 2026by MD Biosciences
Stroke remains one of the highest attrition areas in drug development. Despite decades of preclinical programs showing...
.png?width=1330&height=748&name=Webinar%20Socials%20(8).png)
.png?width=1332&height=748&name=Webinar%20Socials%20(5).png)
.png?width=800&height=924&name=POP%20in%20pigs%20webinar%20(1).png)
